Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab

There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear. We evaluated patients with metastatic melanoma treated with pembrolizuma...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 40; no. 4; pp. 2157 - 2163
Main Authors Simetić, Luka, Blažičević, Krešimir, Međugorac, Kata, Golčić, Marin, Herceg, Davorin
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 01.04.2020
Subjects
Aged
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Biomarkers
Biomarkers, Tumor - analysis
Confidence intervals
Disease-Free Survival
Female
Humans
Immunotherapy
Lung Neoplasms - secondary
Lymphatic Metastasis
Male
Melanoma
Melanoma - drug therapy
Melanoma - metabolism
Melanoma - pathology
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Multivariate analysis
Pembrolizumab
S100 Proteins - analysis
Skin Neoplasms - drug therapy
Skin Neoplasms - metabolism
Skin Neoplasms - pathology
Survival
S100
pembrolizumab
melanoma
immunotherapy
Analysis of survival
Online AccessGet full text

Cover

More Information
Summary:There is a lack of quality biomarkers of survival for patients with metastatic melanoma treated with immunotherapy. Although the baseline level of S100 has prognostic value, its role during/after therapy in survival is unclear. We evaluated patients with metastatic melanoma treated with pembrolizumab with the goal of analysing the relationship between a relative change in S100 level at 12 weeks of immunotherapy and survival. Patients with a relative change in S100 level >145% at 12 weeks of immunotherapy had significantly shorter progression-free (5.1 vs. 18.5 months, p≤0.0001) and overall survival (5.7 vs. 26.3 months, p<0.0001), further confirmed on multivariate analysis with hazard ratio of 32.25 (95% confidence interval=4.78-217.6, p=0.0004) for overall survival. A relative change in S100 level might be useful as a more precise biomarker of survival for patients with metastatic melanoma treated with pembrolizumab.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14175